Author name: Andrew Hryckowian

Andrew Hryckowian is an Assistant Professor and the Judy L. and Sal A. Troia Professor of Gastrointestinal Disease Research in the Departments of Medicine and Medical Microbiology & Immunology at the University of Wisconsin-Madison, USA. He earned his BS from the University of Pittsburgh in 2009, his PhD from the University of Wisconsin-Madison in 2014, and completed his postdoctoral training at Stanford University in 2020. His laboratory’s work leverages his training in bacteriophage (phage) biology, bacterial pathogenesis, and microbiome science to understand how pathogenic and commensal bacteria respond to major drivers of microbiome community ecology in host-associated microbial ecosystems (e.g., inflammation, phages, diet, and microbiome/host-derived metabolites). The ultimate goal of his work is to leverage this understanding to devise novel therapeutics like dietary intervention, precision probiotics, and phage therapy for infectious diseases (e.g., Group B Streptococcus infection, Clostridioides difficile infection) and diseases where the gut microbiome plays an important role (e.g., inflammatory bowel disease). These are especially timely foci given the burgeoning antibiotic resistance crisis and our emerging view of the ways beneficial microbes impact our health.